Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.05 HKD | -0.25% | -5.37% | -88.69% |
Jul. 08 | Sirnaomics Finds No Serious Adverse Events During Phase 1 Study for Coagulation Drug | MT |
Jul. 08 | Sirnaomics Anticogulent Agent Successfully Completes 2nd Cohort of Phase I Clinical Study | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,030 | 649.8 | 401.8 | 45.02 | - | - |
Enterprise Value (EV) 1 | 818.3 | 573.7 | 401.8 | 45.02 | 45.02 | 45.02 |
P/E ratio | -4.84 x | -6.38 x | -4.45 x | -0.37 x | - | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | 22.5 x | 0.64 x | 0.28 x |
EV / Revenue | - | - | - | 22.5 x | 0.64 x | 0.28 x |
EV / EBITDA | -18.7 x | -7.39 x | -5.63 x | -0.33 x | - | - |
EV / FCF | -15.1 x | -7.32 x | - | -0.38 x | -0.28 x | -0.33 x |
FCF Yield | -6.63% | -13.7% | - | -267% | -353% | -307% |
Price to Book | 4.87 x | 5.33 x | 9.99 x | -0.43 x | - | - |
Nbr of stocks (in thousands) | 88,067 | 87,795 | 87,638 | 86,816 | - | - |
Reference price 2 | 11.70 | 7.401 | 4.585 | 0.5185 | 0.5185 | 0.5185 |
Announcement Date | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | 2 | 70 | 161 |
EBITDA 1 | -55.16 | -87.9 | -71.38 | -136 | - | - |
EBIT 1 | -56.79 | -91.83 | -77.54 | -134 | -149 | -131 |
Operating Margin | - | - | - | -6,700% | -212.86% | -81.37% |
Earnings before Tax (EBT) 1 | -215.9 | -97.38 | -84.99 | -134 | - | - |
Net income 1 | -213.1 | -88.3 | -78.69 | -124 | - | - |
Net margin | - | - | - | -6,200% | - | - |
EPS 2 | -2.419 | -1.160 | -1.030 | -1.410 | - | - |
Free Cash Flow 1 | -68.33 | -88.74 | - | -120 | -159 | -138 |
FCF margin | - | - | - | -6,000% | -227.14% | -85.71% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | 212 | 76.1 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -68.3 | -88.7 | - | -120 | -159 | -138 |
ROE (net income / shareholders' equity) | - | -52.9% | -97% | - | - | - |
ROA (Net income/ Total Assets) | - | -43.6% | -65.7% | -119% | - | - |
Assets 1 | - | 202.3 | 119.9 | 104.6 | - | - |
Book Value Per Share 2 | 2.400 | 1.390 | 0.4600 | -1.200 | - | - |
Cash Flow per Share 2 | -3.820 | -1.170 | -0.9200 | -1.430 | - | - |
Capex 1 | 11.4 | 18.8 | - | 5 | 5 | 5 |
Capex / Sales | - | - | - | 250% | 7.14% | 3.11% |
Announcement Date | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-88.69% | 45.12M | |
+18.43% | 122B | |
+19.81% | 112B | |
-23.74% | 19.33B | |
-18.45% | 16.17B | |
-19.97% | 15.6B | |
-49.33% | 14.65B | |
+57.08% | 14.34B | |
+7.95% | 14B | |
+126.04% | 11.29B |
- Stock Market
- Equities
- 2257 Stock
- Financials Sirnaomics Ltd.